CClinicalTrials.gg
RecruitingNCT06135402Updated Sep 23, 2025

Comparison of Laser Treatment With Clobetasol Therapy in Patients With Lichen Sclerosus

An interventional study of Treatment with Monalisa Glide Laser and Treatment with Clobetasol in Lichen Sclerosus, sponsored by Kantonsspital Winterthur KSW. Recruiting at 1 site in Switzerland. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-23.

Sponsored by Kantonsspital Winterthur KSW · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

With this trial the investigators look for the effect of Laser maintenance therapy in patients with vulvar lichen sclerosus compared to the maintenance standard treatment clobetasol propionate.

Read the detailed description

Vulvar Lichen sclerosus (VLS) is a chronic inflammatory cutaneous disorder, which can lead to scarring, impaired sexual function and malignancy. Gold standard treatment is topical corticosteroids (TCS) initially daily for 12 weeks. To avoid new flourishing of the disease a life-long maintenance treatment 2x/week is later recommended. Fractional CO2-Laser has shown a positive effect on vulvovaginal skin quality with improvement of urogenital atrophy and also lichen sclerosus. This randomised trial compares efficacy of laser treatment to TCS maintenance as well as the duration of the laser effect.

02

Conditions studied

  • Lichen Sclerosus
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Pre- or postmenopausal
  • 12 weeks of continuous topical clobetasol treatment completed.
  • Written informed consent
  • German speaking (Study information and IC available only in German)

Exclusion criteria

Exclusion Criteria:

  • Contraindication and limitations for the use of Mona Lisa Glide-Laser as described in the instructions for use
  • Contraindication for the use of topic clobetasol
  • History of vulva laser
  • Immune-suppression
  • Pregnancy or planned pregnancy, breast feeding.
  • Clinically significant concomitant diseases states as severe renal failure, hepatic dysfunction, severe cardiovascular disease, cancer.
  • History of vulvar or pelvic radiation therapy
  • Uncertain vulvar findings, which require a biopsy.
  • Acute vulvitis, especially recurrent genital herpes
  • History of vaginal mesh implantation within 6 months preceding this study
  • Known or suspected non-compliance, drug or alcohol abuse
  • Inability to follow the procedures of the investigation, e.g. due to language problems, psychological disorders, dementia, etc. of the subject
  • Participation in another investigation with an investigational drug or another MD within the 30 days preceding and during the present investigation
  • Previous enrolment into the current investigation
  • Enrolment of the PI, his/her family members, employees and other dependent persons
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Laser group

    3 monthly fractional laser treatment according to the user manual (correct applicator, vulvar and vaginal preset). In between daily local skin care with a drug free product of patients' choice.

    Device: Treatment with Monalisa Glide Laser

  • Active comparator
    Clobetasol group

    Maintenance treatment with vulvar TCS (clobetasol) application 2x/week. Instruction given at trial start and monthly check up for treatment control Daily local skin care with a drug free product of patients' choice.

    Drug: Treatment with Clobetasol

Interventions

  • DeviceTreatment with Monalisa Glide Laser

    3 fractional laser treatment-sessions with Monalisa Glide

  • DrugTreatment with Clobetasol

    Application of Clobetasol twice per week

05

What researchers measure

Primary outcomes

  1. Lichen Score

    The difference between the initial Lichen score and the score at 3 month after treatment start = 1 month after EOT

    Time frame: 3 months

Secondary outcomes

  1. Lichen Score Follow up

    Lichen score at 4, 8 and 12 months after EOT, Scale from 0 (no symptoms) to 12 (symptoms)

    Time frame: 15 months

  2. Vulva assessment Scale

    Vulva assessment scale at 1, 4, 8 and 12 months after EOT, Scale from 0 (no symptoms) to 12 (symptoms)

    Time frame: 15 months

  3. German Pelvic floor questionnaire

    Shortened Pelvic floor questionnaire at 1, 4, 8, 12 months after EOT

    Time frame: 15 months

06

Study locations

1 of 1 sites recruiting
  • Kantonsspital Winterthur
    Winterthur, Canton of Zurich 8401, Switzerland
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06135402
Lead sponsor
Kantonsspital Winterthur KSW
Responsible party
Sponsor
First posted
Nov 18, 2023
Start date
Nov 10, 2023
Primary completion
Nov 1, 2027 (estimated)
Completion
Nov 1, 2027 (estimated)
Last update
Sep 23, 2025

Study contacts

Rebecca R Zachariah, MD
Contact
rebecca.zachariah@ksw.ch
+41522663173
Susanne Forst
Contact
susanne.forst@ksw.ch
+41522663387
Gesine Meili, MD
principal investigator · Clinic of obstetrics and gynecology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion